REGENXBIO Shares Tumble 37% Despite Duchenne Gene Therapy Trial Success
REGENXBIO (RGNX) stock plummeted 37% to $6.31 despite positive Phase III data for RGX-202, as two serious adverse events and FDA approval doubts overshadowed the results.
Technology
